home All News open_in_new Full Article

Roche legt positive Langzeitdaten zu Krebsmittel Perjeta vor

Pharmazie - Die langfristige Nachbeobachtung beim Roche-Krebsmittel Perjeta zeigt einen klinisch bedeutsamen Überlebensvorteil.


today 3 w. ago attach_file Other

attach_file Other
attach_file Other
attach_file Other
attach_file Economics
attach_file Other
attach_file Events
attach_file Other
attach_file Politics
attach_file Other
attach_file Economics
attach_file Other
attach_file Other
attach_file Politics
attach_file Other
attach_file Economics
attach_file Other
attach_file Other
attach_file Other
attach_file Other
attach_file Other


ID: 1749548670
Add Watch Country

arrow_drop_down